Becton, Dickinson and Company
BD Announces Q3 2025 Financial Results and Raises Guidance
Summary
On August 7, 2025, Becton, Dickinson and Company (BD) reported its Q3 2025 financial results, revealing a 10.4% increase in revenue and adjusted diluted EPS of $3.68. The company raised its full-year adjusted diluted EPS guidance to $14.30 to $14.45, reflecting a $0.18 increase at the midpoint. This update followed the announcement of a definitive agreement to combine BD's Biosciences and Diagnostic Solutions business with Waters Corporation, expected to create a leading life science and diagnostic company.
Profitelligence Alerts
Get alerts for BDX
Be first to know when Becton, Dickinson and Company files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Becton, Dickinson and Company
Becton, Dickinson and Company, commonly known as BD, is a prominent American multinational corporation engaged in the development and manufacture of a diverse range of medical devices, instrument systems, and reagents. A key player in the healthcare industry, BD focuses on improving medical discovery, diagnostics, and the delivery of care. BD's products are instrumental in supporting healthcare professionals worldwide in enhancing patient safety and reducing the risks associated with healthcare workers. The company operates across three main segments: BD Medical, BD Life Sciences, and BD Interventional, impacting various sectors such as pharmaceuticals, hospital healthcare systems, and clinical laboratories. With a strong commitment to innovation and quality, Becton, Dickinson and Company contributes significantly to advancements in patient care, operating efficiency in medical settings, and is noted for its commitment to addressing healthcare challenges on a global scale. Headquartered in Franklin Lakes, New Jersey, BD maintains a robust presence across numerous countries, underpinning its influential role in the evolution and improvement of global healthcare infrastructure.
Official SEC Documents
Advertisement